Hotline: +86-18022463983    020-85206863

Global and United States HR+HER2- Breast Cancer Market Report & Forecast 2022-2028

Published Date: 2022-05-23   |   Pages: 96   |   Tables: 136   |  Medical Care

HR+/HER2-Breast Cancer

Market Analysis and Insights: Global and United States HR+HER2- Breast Cancer Market

This report focuses on global and United States HR+HER2- Breast Cancer market, also covers the segmentation data of other regions in regional level and county level.

Due to the COVID-19 pandemic, the global HR+HER2- Breast Cancer market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, by Type, CDK4/6 Inhibitors accounting for % of the HR+HER2- Breast Cancer global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While by Application, Hospitals was the leading segment, accounting for over percent market share in 2021, and altered to an % CAGR throughout this forecast period.

In United States the HR+HER2- Breast Cancer market size is expected to grow from US$ million in 2021 to US$ million by 2028, at a CAGR of % during the forecast period.

Global HR+HER2- Breast Cancer Scope and Market Size

HR+HER2- Breast Cancer market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global HR+HER2- Breast Cancer market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

For United States market, this report focuses on the HR+HER2- Breast Cancer market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.

Segment by Type

CDK4/6 Inhibitors

PARP Inhibitors

PI3K Inhibitor

Others

Segment by Application

Hospitals

Cancer Center

Medical Research and Academic Institutions

Ambulatory Surgical Centers

Others

By Region

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Indonesia

Thailand

Malaysia

Philippines

Vietnam

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

By Company

Jiangsu HengRui Medicine

Odonate Therapeutics

Radius Pharmaceuticals

Immunomedics

Roche Group

Syndax Pharmaceuticals

Merck

Eagle Pharmaceuticals

Merrimack Pharmaceuticals

GlaxoSmithKline

Millennium Pharmaceuticals

Bayer

Research Methodology

The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:


Stage 1 SECONDARY RESEARCH

The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.

 

Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES

After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.

 

Stage 3 ANALYSIS OF THE GATHERED DATA

The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.

 

Stage 4 QUANTITATIVE DATA

The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.

 

Stage 5 QUALITY CONTROL

Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.

 

1 Study Coverage

1.1 HR+HER2- Breast Cancer Revenue in HR+HER2- Breast Cancer Business (2017-2022) & (US$ Million) Introduction

1.2 Global HR+HER2- Breast Cancer Outlook 2017 VS 2022 VS 2028

1.2.1 Global HR+HER2- Breast Cancer Market Size for the Year 2017-2028

1.2.2 Global HR+HER2- Breast Cancer Market Size for the Year 2017-2028

1.3 HR+HER2- Breast Cancer Market Size, United States VS Global, 2017 VS 2022 VS 2028

1.3.1 The Market Share of United States HR+HER2- Breast Cancer in Global, 2017 VS 2022 VS 2028

1.3.2 The Growth Rate of HR+HER2- Breast Cancer Market Size, United States VS Global, 2017 VS 2022 VS 2028

1.4 HR+HER2- Breast Cancer Market Dynamics

1.4.1 HR+HER2- Breast Cancer Industry Trends

1.4.2 HR+HER2- Breast Cancer Market Drivers

1.4.3 HR+HER2- Breast Cancer Market Challenges

1.4.4 HR+HER2- Breast Cancer Market Restraints

1.5 Study Objectives

1.6 Years Considered

2 HR+HER2- Breast Cancer by Type

2.1 HR+HER2- Breast Cancer Market Segment by Type

2.1.1 CDK4/6 Inhibitors

2.1.2 PARP Inhibitors

2.1.3 PI3K Inhibitor

2.1.4 Others

2.2 Global HR+HER2- Breast Cancer Market Size by Type (2017, 2022 & 2028)

2.3 Global HR+HER2- Breast Cancer Market Size by Type (2017-2028)

2.4 United States HR+HER2- Breast Cancer Market Size by Type (2017, 2022 & 2028)

2.5 United States HR+HER2- Breast Cancer Market Size by Type (2017-2028)

3 HR+HER2- Breast Cancer by Application

3.1 HR+HER2- Breast Cancer Market Segment by Application

3.1.1 Hospitals

3.1.2 Cancer Center

3.1.3 Medical Research and Academic Institutions

3.1.4 Ambulatory Surgical Centers

3.1.5 Others

3.2 Global HR+HER2- Breast Cancer Market Size by Application (2017, 2022 & 2028)

3.3 Global HR+HER2- Breast Cancer Market Size by Application (2017-2028)

3.4 United States HR+HER2- Breast Cancer Market Size by Application (2017, 2022 & 2028)

3.5 United States HR+HER2- Breast Cancer Market Size by Application (2017-2028)

4 Global HR+HER2- Breast Cancer Competitor Landscape by Company

4.1 Global HR+HER2- Breast Cancer Market Size by Company

4.1.1 Top Global HR+HER2- Breast Cancer Companies Ranked by Revenue (2021)

4.1.2 Global HR+HER2- Breast Cancer Revenue by Player (2017-2022)

4.2 Global HR+HER2- Breast Cancer Concentration Ratio (CR)

4.2.1 HR+HER2- Breast Cancer Market Concentration Ratio (CR) (2017-2022)

4.2.2 Global Top 5 and Top 10 Largest Companies of HR+HER2- Breast Cancer in 2021

4.2.3 Global HR+HER2- Breast Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

4.3 Global HR+HER2- Breast Cancer Headquarters, Revenue in HR+HER2- Breast Cancer Business (2017-2022) & (US$ Million) Type

4.3.1 Global HR+HER2- Breast Cancer Headquarters and Area Served

4.3.2 Global HR+HER2- Breast Cancer Companies Revenue in HR+HER2- Breast Cancer Business (2017-2022) & (US$ Million) Type

4.3.3 Date of International Companies Enter into HR+HER2- Breast Cancer Market

4.4 Companies Mergers & Acquisitions, Expansion Plans

4.5 United States HR+HER2- Breast Cancer Market Size by Company

4.5.1 Top HR+HER2- Breast Cancer Players in United States, Ranked by Revenue (2021)

4.5.2 United States HR+HER2- Breast Cancer Revenue by Players (2020, 2021 & 2022)

5 Global HR+HER2- Breast Cancer Market Size by Region

5.1 Global HR+HER2- Breast Cancer Market Size by Region: 2017 VS 2022 VS 2028

5.2 Global HR+HER2- Breast Cancer Market Size by Region (2017-2028)

5.2.1 Global HR+HER2- Breast Cancer Market Size by Region: 2017-2022

5.2.2 Global HR+HER2- Breast Cancer Market Size by Region (2023-2028)

6 Segment in Region Level & Country Level

6.1 North America

6.1.1 North America HR+HER2- Breast Cancer Market Size YoY Growth 2017-2028

6.1.2 North America HR+HER2- Breast Cancer Market Facts & Figures by Country (2017, 2022 & 2028)

6.1.3 U.S.

6.1.4 Canada

6.2 Asia-Pacific

6.2.1 Asia-Pacific HR+HER2- Breast Cancer Market Size YoY Growth 2017-2028

6.2.2 Asia-Pacific HR+HER2- Breast Cancer Market Facts & Figures by Region (2017, 2022 & 2028)

6.2.3 China

6.2.4 Japan

6.2.5 South Korea

6.2.6 India

6.2.7 Australia

6.2.8 Taiwan

6.2.9 Indonesia

6.2.10 Thailand

6.2.11 Malaysia

6.2.12 Philippines

6.3 Europe

6.3.1 Europe HR+HER2- Breast Cancer Market Size YoY Growth 2017-2028

6.3.2 Europe HR+HER2- Breast Cancer Market Facts & Figures by Country (2017, 2022 & 2028)

6.3.3 Germany

6.3.4 France

6.3.5 U.K.

6.3.6 Italy

6.3.7 Russia

6.4 Latin America

6.4.1 Latin America HR+HER2- Breast Cancer Market Size YoY Growth 2017-2028

6.4.2 Latin America HR+HER2- Breast Cancer Market Facts & Figures by Country (2017, 2022 & 2028)

6.4.3 Mexico

6.4.4 Brazil

6.4.5 Argentina

6.5 Middle East and Africa

6.5.1 Middle East and Africa HR+HER2- Breast Cancer Market Size YoY Growth 2017-2028

6.5.2 Middle East and Africa HR+HER2- Breast Cancer Market Facts & Figures by Country (2017, 2022 & 2028)

6.5.3 Turkey

6.5.4 Saudi Arabia

6.5.5 UAE

7 Company Profiles

7.1 Jiangsu HengRui Medicine

7.1.1 Jiangsu HengRui Medicine Company Details

7.1.2 Jiangsu HengRui Medicine Business Overview

7.1.3 Jiangsu HengRui Medicine HR+HER2- Breast Cancer Introduction

7.1.4 Jiangsu HengRui Medicine Revenue in HR+HER2- Breast Cancer Business (2017-2022)

7.1.5 Jiangsu HengRui Medicine Recent Development

7.2 Odonate Therapeutics

7.2.1 Odonate Therapeutics Company Details

7.2.2 Odonate Therapeutics Business Overview

7.2.3 Odonate Therapeutics HR+HER2- Breast Cancer Introduction

7.2.4 Odonate Therapeutics Revenue in HR+HER2- Breast Cancer Business (2017-2022)

7.2.5 Odonate Therapeutics Recent Development

7.3 Radius Pharmaceuticals

7.3.1 Radius Pharmaceuticals Company Details

7.3.2 Radius Pharmaceuticals Business Overview

7.3.3 Radius Pharmaceuticals HR+HER2- Breast Cancer Introduction

7.3.4 Radius Pharmaceuticals Revenue in HR+HER2- Breast Cancer Business (2017-2022)

7.3.5 Radius Pharmaceuticals Recent Development

7.4 Immunomedics

7.4.1 Immunomedics Company Details

7.4.2 Immunomedics Business Overview

7.4.3 Immunomedics HR+HER2- Breast Cancer Introduction

7.4.4 Immunomedics Revenue in HR+HER2- Breast Cancer Business (2017-2022)

7.4.5 Immunomedics Recent Development

7.5 Roche Group

7.5.1 Roche Group Company Details

7.5.2 Roche Group Business Overview

7.5.3 Roche Group HR+HER2- Breast Cancer Introduction

7.5.4 Roche Group Revenue in HR+HER2- Breast Cancer Business (2017-2022)

7.5.5 Roche Group Recent Development

7.6 Syndax Pharmaceuticals

7.6.1 Syndax Pharmaceuticals Company Details

7.6.2 Syndax Pharmaceuticals Business Overview

7.6.3 Syndax Pharmaceuticals HR+HER2- Breast Cancer Introduction

7.6.4 Syndax Pharmaceuticals Revenue in HR+HER2- Breast Cancer Business (2017-2022)

7.6.5 Syndax Pharmaceuticals Recent Development

7.7 Merck

7.7.1 Merck Company Details

7.7.2 Merck Business Overview

7.7.3 Merck HR+HER2- Breast Cancer Introduction

7.7.4 Merck Revenue in HR+HER2- Breast Cancer Business (2017-2022)

7.7.5 Merck Recent Development

7.8 Eagle Pharmaceuticals

7.8.1 Eagle Pharmaceuticals Company Details

7.8.2 Eagle Pharmaceuticals Business Overview

7.8.3 Eagle Pharmaceuticals HR+HER2- Breast Cancer Introduction

7.8.4 Eagle Pharmaceuticals Revenue in HR+HER2- Breast Cancer Business (2017-2022)

7.8.5 Eagle Pharmaceuticals Recent Development

7.9 Merrimack Pharmaceuticals

7.9.1 Merrimack Pharmaceuticals Company Details

7.9.2 Merrimack Pharmaceuticals Business Overview

7.9.3 Merrimack Pharmaceuticals HR+HER2- Breast Cancer Introduction

7.9.4 Merrimack Pharmaceuticals Revenue in HR+HER2- Breast Cancer Business (2017-2022)

7.9.5 Merrimack Pharmaceuticals Recent Development

7.10 GlaxoSmithKline

7.10.1 GlaxoSmithKline Company Details

7.10.2 GlaxoSmithKline Business Overview

7.10.3 GlaxoSmithKline HR+HER2- Breast Cancer Introduction

7.10.4 GlaxoSmithKline Revenue in HR+HER2- Breast Cancer Business (2017-2022)

7.10.5 GlaxoSmithKline Recent Development

7.11 Millennium Pharmaceuticals

7.11.1 Millennium Pharmaceuticals Company Details

7.11.2 Millennium Pharmaceuticals Business Overview

7.11.3 Millennium Pharmaceuticals HR+HER2- Breast Cancer Introduction

7.11.4 Millennium Pharmaceuticals Revenue in HR+HER2- Breast Cancer Business (2017-2022)

7.11.5 Millennium Pharmaceuticals Recent Development

7.12 Bayer

7.12.1 Bayer Company Details

7.12.2 Bayer Business Overview

7.12.3 Bayer HR+HER2- Breast Cancer Introduction

7.12.4 Bayer Revenue in HR+HER2- Breast Cancer Business (2017-2022)

7.12.5 Bayer Recent Development

8 Research Findings and Conclusion

9 Appendix

9.1 Research Methodology

9.1.1 Methodology/Research Approach

9.1.2 Data Source

9.2 Author Details

9.3 Disclaimer

List of Tables

Table 1. HR+HER2- Breast Cancer Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028)

Table 2. HR+HER2- Breast Cancer Market Trends

Table 3. HR+HER2- Breast Cancer Market Drivers

Table 4. HR+HER2- Breast Cancer Market Challenges

Table 5. HR+HER2- Breast Cancer Market Restraints

Table 6. Global HR+HER2- Breast Cancer Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)

Table 7. United States HR+HER2- Breast Cancer Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)

Table 8. Global HR+HER2- Breast Cancer Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)

Table 9. United States HR+HER2- Breast Cancer Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)

Table 10. Top HR+HER2- Breast Cancer Companies in Global Market, Ranking by Revenue (2021)

Table 11. Global HR+HER2- Breast Cancer Revenue by Player, (US$ Million), 2017-2022

Table 12. Global HR+HER2- Breast Cancer Revenue Share by Player, 2017-2022

Table 13. Global HR+HER2- Breast Cancer Companies Market Concentration Ratio (CR5 and HHI)

Table 14. Global HR+HER2- Breast Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in HR+HER2- Breast Cancer as of 2021)

Table 15. Top Players of HR+HER2- Breast Cancer in Global Market, Headquarters and Area Served

Table 16. Companies Revenue in HR+HER2- Breast Cancer Business (2017-2022) & (US$ Million) Type

Table 17. Date of International Companies Enter into HR+HER2- Breast Cancer Market

Table 18. Companies Mergers & Acquisitions, Expansion Plans

Table 19. Top HR+HER2- Breast Cancer Players in United States Market, Ranking by Revenue (2021)

Table 20. United States HR+HER2- Breast Cancer Revenue by Players, (US$ Million), 2020, 2021 & 2022

Table 21. United States HR+HER2- Breast Cancer Revenue Share by Players, 2020, 2021 & 2022

Table 22. Global HR+HER2- Breast Cancer Market Size by Region (US$ Million): 2017 VS 2022 VS 2028

Table 23. Global HR+HER2- Breast Cancer Market Size by Region (2017-2022) & (US$ Million)

Table 24. Global HR+HER2- Breast Cancer Market Size Forecast by Region (2023-2028) & (US$ Million)

Table 25. North America HR+HER2- Breast Cancer Sales in Value by Country (2017-2028) & (US$ Million)

Table 26. Asia Pacific HR+HER2- Breast Cancer Sales in Value by Region (2017-2028) & (US$ Million)

Table 27. Europe HR+HER2- Breast Cancer Sales in Value by Country (2017-2028) & (US$ Million)

Table 28. Latin Americaa HR+HER2- Breast Cancer Sales in Value by Country (2017-2028) & (US$ Million)

Table 29. Middle East and Africa HR+HER2- Breast Cancer Sales in Value by Country (2017-2028) & (US$ Million)

Table 30. Jiangsu HengRui Medicine Company Details

Table 31. Jiangsu HengRui Medicine Business Overview

Table 32. Jiangsu HengRui Medicine HR+HER2- Breast Cancer Product

Table 33. Jiangsu HengRui Medicine Revenue in HR+HER2- Breast Cancer Business (2017-2022) & (US$ Million)

Table 34. Jiangsu HengRui Medicine Recent Development

Table 35. Odonate Therapeutics Company Details

Table 36. Odonate Therapeutics Business Overview

Table 37. Odonate Therapeutics HR+HER2- Breast Cancer Product

Table 38. Odonate Therapeutics Revenue in HR+HER2- Breast Cancer Business (2017-2022) & (US$ Million)

Table 39. Odonate Therapeutics Recent Development

Table 40. Radius Pharmaceuticals Company Details

Table 41. Radius Pharmaceuticals Business Overview

Table 42. Radius Pharmaceuticals HR+HER2- Breast Cancer Product

Table 43. Radius Pharmaceuticals Revenue in HR+HER2- Breast Cancer Business (2017-2022) & (US$ Million)

Table 44. Radius Pharmaceuticals Recent Development

Table 45. Immunomedics Company Details

Table 46. Immunomedics Business Overview

Table 47. Immunomedics HR+HER2- Breast Cancer Product

Table 48. Immunomedics Revenue in HR+HER2- Breast Cancer Business (2017-2022) & (US$ Million)

Table 49. Immunomedics Recent Development

Table 50. Roche Group Company Details

Table 51. Roche Group Business Overview

Table 52. Roche Group HR+HER2- Breast Cancer Product

Table 53. Roche Group Revenue in HR+HER2- Breast Cancer Business (2017-2022) & (US$ Million)

Table 54. Roche Group Recent Development

Table 55. Syndax Pharmaceuticals Company Details

Table 56. Syndax Pharmaceuticals Business Overview

Table 57. Syndax Pharmaceuticals HR+HER2- Breast Cancer Product

Table 58. Syndax Pharmaceuticals Revenue in HR+HER2- Breast Cancer Business (2017-2022) & (US$ Million)

Table 59. Syndax Pharmaceuticals Recent Development

Table 60. Merck Company Details

Table 61. Merck Business Overview

Table 62. Merck HR+HER2- Breast Cancer Product

Table 63. Merck Revenue in HR+HER2- Breast Cancer Business (2017-2022) & (US$ Million)

Table 64. Merck Recent Development

Table 65. Eagle Pharmaceuticals Company Details

Table 66. Eagle Pharmaceuticals Business Overview

Table 67. Eagle Pharmaceuticals HR+HER2- Breast Cancer Product

Table 68. Eagle Pharmaceuticals Revenue in HR+HER2- Breast Cancer Business (2017-2022) & (US$ Million)

Table 69. Eagle Pharmaceuticals Recent Development

Table 70. Merrimack Pharmaceuticals Company Details

Table 71. Merrimack Pharmaceuticals Business Overview

Table 72. Merrimack Pharmaceuticals HR+HER2- Breast Cancer Product

Table 73. Merrimack Pharmaceuticals Revenue in HR+HER2- Breast Cancer Business (2017-2022) & (US$ Million)

Table 74. Merrimack Pharmaceuticals Recent Development

Table 75. GlaxoSmithKline Company Details

Table 76. GlaxoSmithKline Business Overview

Table 77. GlaxoSmithKline HR+HER2- Breast Cancer Product

Table 78. GlaxoSmithKline Revenue in HR+HER2- Breast Cancer Business (2017-2022) & (US$ Million)

Table 79. GlaxoSmithKline Recent Development

Table 80. Millennium Pharmaceuticals Company Details

Table 81. Millennium Pharmaceuticals Business Overview

Table 82. Millennium Pharmaceuticals HR+HER2- Breast Cancer Product

Table 83. Millennium Pharmaceuticals Revenue in HR+HER2- Breast Cancer Business (2017-2022) & (US$ Million)

Table 84. Millennium Pharmaceuticals Recent Development

Table 85. Bayer Company Details

Table 86. Bayer Business Overview

Table 87. Bayer HR+HER2- Breast Cancer Product

Table 88. Bayer Revenue in HR+HER2- Breast Cancer Business (2017-2022) & (US$ Million)

Table 89. Bayer Recent Development

Table 90. Research Programs/Design for This Report

Table 91. Key Data Information from Secondary Sources

Table 92. Key Data Information from Primary Sources

List of Figures

Figure 1. HR+HER2- Breast Cancer Product Picture

Figure 2. Global HR+HER2- Breast Cancer Market Size, (US$ Million), 2017 VS 2022 VS 2028

Figure 3. Global HR+HER2- Breast Cancer Market Size 2017-2028 (US$ Million)

Figure 4. United States HR+HER2- Breast Cancer Market Size, (US$ Million), 2017 VS 2022 VS 2028

Figure 5. United States HR+HER2- Breast Cancer Market Size 2017-2028 (US$ Million)

Figure 6. United States HR+HER2- Breast Cancer Market Share in Global 2017-2028

Figure 7. HR+HER2- Breast Cancer Report Years Considered

Figure 8. Product Picture of CDK4/6 Inhibitors

Figure 9. Product Picture of PARP Inhibitors

Figure 10. Product Picture of PI3K Inhibitor

Figure 11. Product Picture of Others

Figure 12. Global HR+HER2- Breast Cancer Market Share by Type in 2022 & 2028

Figure 13. Global HR+HER2- Breast Cancer Market Size by Type (2017-2028) & (US$ Million)

Figure 14. Global HR+HER2- Breast Cancer Market Share by Type (2017-2028)

Figure 15. United States HR+HER2- Breast Cancer Market Share by Type in 2022 & 2028

Figure 16. United States HR+HER2- Breast Cancer Market Size by Type (2017-2028) & (US$ Million)

Figure 17. United States HR+HER2- Breast Cancer Market Share by Type (2017-2028)

Figure 18. Product Picture of Hospitals

Figure 19. Product Picture of Cancer Center

Figure 20. Product Picture of Medical Research and Academic Institutions

Figure 21. Product Picture of Ambulatory Surgical Centers

Figure 22. Product Picture of Others

Figure 23. Global HR+HER2- Breast Cancer Market Share by Application in 2022 & 2028

Figure 24. Global HR+HER2- Breast Cancer Market Size by Application (2017-2028) & (US$ Million)

Figure 25. Global HR+HER2- Breast Cancer Market Share by Application (2017-2028)

Figure 26. United States HR+HER2- Breast Cancer Market Share by Application in 2022 & 2028

Figure 27. United States HR+HER2- Breast Cancer Market Size by Application (2017-2028) & (US$ Million)

Figure 28. United States HR+HER2- Breast Cancer Market Share by Application (2017-2028)

Figure 29. North America HR+HER2- Breast Cancer Market Size Growth Rate 2017-2028 (US$ Million)

Figure 30. U.S. HR+HER2- Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 31. Canada HR+HER2- Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 32. Europe HR+HER2- Breast Cancer Market Size Growth Rate 2017-2028 (US$ Million)

Figure 33. Germany HR+HER2- Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 34. France HR+HER2- Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 35. U.K. HR+HER2- Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 36. Italy HR+HER2- Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 37. Russia HR+HER2- Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 38. Asia-Pacific HR+HER2- Breast Cancer Market Size Growth Rate 2017-2028 (US$ Million)

Figure 39. China HR+HER2- Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 40. Japan HR+HER2- Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 41. South Korea HR+HER2- Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 42. India HR+HER2- Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 43. Australia HR+HER2- Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 44. Taiwan HR+HER2- Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 45. Indonesia HR+HER2- Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 46. Thailand HR+HER2- Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 47. Malaysia HR+HER2- Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 48. Philippines HR+HER2- Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 49. Latin America HR+HER2- Breast Cancer Market Size Growth Rate 2017-2028 (US$ Million)

Figure 50. Mexico HR+HER2- Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 51. Brazil HR+HER2- Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 52. Argentina HR+HER2- Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 53. Middle East & Africa HR+HER2- Breast Cancer Market Size Growth Rate 2017-2028 (US$ Million)

Figure 54. Turkey HR+HER2- Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 55. Saudi Arabia HR+HER2- Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 56. UAE HR+HER2- Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 57. Jiangsu HengRui Medicine Revenue Growth Rate in HR+HER2- Breast Cancer Business (2017-2022)

Figure 58. Odonate Therapeutics Revenue Growth Rate in HR+HER2- Breast Cancer Business (2017-2022)

Figure 59. Radius Pharmaceuticals Revenue Growth Rate in HR+HER2- Breast Cancer Business (2017-2022)

Figure 60. Immunomedics Revenue Growth Rate in HR+HER2- Breast Cancer Business (2017-2022)

Figure 61. Roche Group Revenue Growth Rate in HR+HER2- Breast Cancer Business (2017-2022)

Figure 62. Syndax Pharmaceuticals Revenue Growth Rate in HR+HER2- Breast Cancer Business (2017-2022)

Figure 63. Merck Revenue Growth Rate in HR+HER2- Breast Cancer Business (2017-2022)

Figure 64. Eagle Pharmaceuticals Revenue Growth Rate in HR+HER2- Breast Cancer Business (2017-2022)

Figure 65. Merrimack Pharmaceuticals Revenue Growth Rate in HR+HER2- Breast Cancer Business (2017-2022)

Figure 66. GlaxoSmithKline Revenue Growth Rate in HR+HER2- Breast Cancer Business (2017-2022)

Figure 67. Millennium Pharmaceuticals Revenue Growth Rate in HR+HER2- Breast Cancer Business (2017-2022)

Figure 68. Bayer Revenue Growth Rate in HR+HER2- Breast Cancer Business (2017-2022)

Figure 69. Bottom-up and Top-down Approaches for This Report

Figure 70. Data Triangulation

Figure 71. Key Executives Interviewed

Our Clients